PixarBio Corp

(PXRB)

By |

Non-Opiate Post-Operative, Acute & Chronic Pain System

One year after hip, knee and spine surgeries, 80% of patients report that pain is moderate to severe after surgery. Pain limits the patient’s physical therapy outcome and thereby reduces the possibility of a full recovery.

NanoMedicines and Microparticles

Nanoscale Delivery Systems and Microparticles provide new biomaterials platform opportunities for targeted drug delivery. PixarBio is using patent pending formulations of FDA approved biomaterials and FDA approved non-opiate drugs to target key neurological areas to treat pain.

PixarBio cofounder Frank Reynolds has an in-depth knowledge of the needs of the postsurgical pain, acute pain and chronic pain markets. Frank’s passion for delivering improved quality of life for all neurological patients drives PixarBio’s commitment to concurrently engineer new treatments for a wide range of painful conditions. We believe that these treatments may reduce drug addiction associated with opiate pain killers and improve clinical outcomes.

Our founders’ expertise in cGMP manufacturing of biomaterials with extensive safety records and a history of FDA regulatory approvals has given PixarBio the insight in-house on how to reach those goals by applying our core competencies to developing new treatment options for doctors and patients.

With our team’s expertise on over 60 products approved by the FDA to start human studies, we have unmatched experience in the drug delivery system space and a track record of successfully developing FDA approved products.

In 2016, NeuroRelease is the only non-opiate product in process at the US FDA that can treat post-op pain treatment LONGER THAN 5 DAYS and we last 14 days defeating Rebound Pain.

PixarBio will lead the Non-Opiate Revolution around Non-Addictive Pain treatments.

NeuroRelease FDA approval is expected in 2018, mitigates sensory (pain) signaling without effecting locomotion (moving) signals and we have the potential to replace morphine in the clinic.

  • To defeat Rebound Pain over 40 surgical procedures require 14 days of post-op pain treatment
  • 100% of surgeons prefer non addictive pain treatments over morphine
  • Over 90% of patients prefer non-addictive post op pain treatment over morphine

NeuroRelease is expected to receive FDA approval for post-op pain in 2018, and with our growing team of industry experts NeuroRelease will create a new clinical franchise in medicine around NeuroRelease’s pain product pipeline.

More importantly, we’ll change the way medicine is delivered throughout the world.

Lead pain treatments will last up to 14 days, 7 days, 90 days, for the clinic and 4-8 hours for dentistry.

2016 Current Non-Opioid/Non-Opiates Options or Under Review by the FDA

2017- Clinical Studies

As a 505b2 product going through the FDA, each study will have two phase studies (not three) to receive FDA Approval by the end of 2018

Each study will have two phases for FDA Approval.

  • Small Nerve- Shoulder Surgery Pain Study with a total of 500 patients
  • Large Nerve- Knee Replacement Pain Study with a total of 500 patients

These two studies will permit the NeuroRelease to be Marketed as a nerve block anywhere in the body

PixarBio Answers Society Mandate for Non addictive Pain Treatment

Over 40 different surgical procedures, where 50% of more of surgical physicians need a 14 day post op treatment

  • NeuroRelease Meets Societies Unmet Medical Need to replace Opiates
  • Clinic based addiction is whipped out for NeuroRelease patients.
  • NeuroRelease patients go home quickly reducing hospital stay
  • Patients begin physical therapy and rehabilitation quickly.

As NeuroRelease has evolved we have already extended NeuroRelease to spinal cord injury, Epilepsy, and Parkinson’s Disease and the platform demonstrates great promise.

NeuroRelease vs. Exparel - 2018 Real World Competition

NeuroReleaseTM vs. Exparel (Liposomal bupivacaine – FDA approved 72-hours post-op soft tissue pain)

NeuroRelease vs. Bupivacaine

FDA Study Face-Off: NeuroRelease vs. Bupivacaine

TEDxBoston – Frank Reynolds Changing the Face of Neuroscience

Additional Information

PixarBio Corp

Profile

PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury.

Contact Information

Website: www.pixarbio.com
Main Phone: +1 617 803-8838
Address: 200 Boston Avenue
Address 2: Suite 1875
State: MA
City / Town: Medford
Country: USA
Postal Code: 02155

Issuer Information

Exchange: OTCQB
CEO: Frank Reynolds
Employees: 1
Issuer Type: CS - Common Stock
Sector/Industry: Healthcare
NAICS: Pharmaceutical P
$ 2.90 $ 0. (0.00%)
Last Price 2.90 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close 2.90
Last Trade Volume 0 52 Wk Hi 30.00 52 Wk Low 2.70
Market Cap 142.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 49,096,000.00 EPS (TTM) 0.00 PE Ratio N/A Exchange OTCPK